WO2000069895A3 - Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins - Google Patents

Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins Download PDF

Info

Publication number
WO2000069895A3
WO2000069895A3 PCT/US2000/012909 US0012909W WO0069895A3 WO 2000069895 A3 WO2000069895 A3 WO 2000069895A3 US 0012909 W US0012909 W US 0012909W WO 0069895 A3 WO0069895 A3 WO 0069895A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
modified form
polar
bufornin
therapeutic agent
Prior art date
Application number
PCT/US2000/012909
Other languages
French (fr)
Other versions
WO2000069895A2 (en
Inventor
Gregory E Garcia
Richard K Gordon
Deborah R Moorad
Bhupendra P Doctor
Original Assignee
Us Army Med Res Mat Command
Gregory E Garcia
Richard K Gordon
Deborah R Moorad
Bhupendra P Doctor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Med Res Mat Command, Gregory E Garcia, Richard K Gordon, Deborah R Moorad, Bhupendra P Doctor filed Critical Us Army Med Res Mat Command
Priority to CA002369369A priority Critical patent/CA2369369A1/en
Priority to IL14641100A priority patent/IL146411A0/en
Priority to AU61975/00A priority patent/AU781608B2/en
Priority to JP2000618311A priority patent/JP2003502023A/en
Priority to EP00948495A priority patent/EP1179022A2/en
Publication of WO2000069895A2 publication Critical patent/WO2000069895A2/en
Publication of WO2000069895A3 publication Critical patent/WO2000069895A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The compounds of the invention are generally described by the formula (I): X1X2B3X4B5X*6X7X8B9X10B11X12B13X14B15X16B17X*18X*19B20X21X22X23Q24F25Z*26X27X28B29X30B31B32X33X34B35B36X37Z38Z39, and the salts, esters, amides, and acyl forms thereof. Up to 15 amino acids may be truncated from the N-terminus and up to 6 amino acids may be truncated from the C-terminus. Each position represented by a letter indicates a single amino acid residue wherein B is a basic or polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a small or polar/large amino acid or a modified form thereof; Z is a polar/large or hydrophobic amino acid or a modified form thereof; Z* is Proline or a polar/large or hydrophobic amino acid or a modified form thereof. These compounds may be used to inhibit the protease activity of Botulinum B and tetanus toxins.
PCT/US2000/012909 1999-05-14 2000-05-11 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins WO2000069895A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002369369A CA2369369A1 (en) 1999-05-14 2000-05-11 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
IL14641100A IL146411A0 (en) 1999-05-14 2000-05-11 Buforin i as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
AU61975/00A AU781608B2 (en) 1999-05-14 2000-05-11 Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
JP2000618311A JP2003502023A (en) 1999-05-14 2000-05-11 Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxin
EP00948495A EP1179022A2 (en) 1999-05-14 2000-05-11 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13421699P 1999-05-14 1999-05-14
US60/134,216 1999-05-14

Publications (2)

Publication Number Publication Date
WO2000069895A2 WO2000069895A2 (en) 2000-11-23
WO2000069895A3 true WO2000069895A3 (en) 2001-08-09

Family

ID=22462297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012909 WO2000069895A2 (en) 1999-05-14 2000-05-11 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Country Status (6)

Country Link
EP (1) EP1179022A2 (en)
JP (1) JP2003502023A (en)
AU (1) AU781608B2 (en)
CA (1) CA2369369A1 (en)
IL (1) IL146411A0 (en)
WO (1) WO2000069895A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
KR20020051124A (en) * 2000-12-22 2002-06-28 이한웅 Anti-cancer Agent Comprising Bufforin Derivatives
JP2003009897A (en) 2001-07-03 2003-01-14 Keiji Oguma Method for separating and purifying botulinus toxin
EP2153848A3 (en) 2005-01-27 2010-07-21 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
CN111100195B (en) * 2018-10-25 2024-04-09 安尼根有限公司 Buforin derivative and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033850A1 (en) * 1994-06-03 1995-12-14 Microbiological Research Authority Toxin assay
WO1998007440A1 (en) * 1996-08-24 1998-02-26 Samyang Genex Co., Ltd. A novel antimicrobial peptide isolated from bufo bufo gargarizans
WO1998054336A1 (en) * 1997-05-28 1998-12-03 Samyang Genex Corporation Method for mass production of antimicrobial peptide
WO1999037664A1 (en) * 1998-01-22 1999-07-29 Samyang Genex Corporation Novel peptides having biological activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033850A1 (en) * 1994-06-03 1995-12-14 Microbiological Research Authority Toxin assay
WO1998007440A1 (en) * 1996-08-24 1998-02-26 Samyang Genex Co., Ltd. A novel antimicrobial peptide isolated from bufo bufo gargarizans
WO1998054336A1 (en) * 1997-05-28 1998-12-03 Samyang Genex Corporation Method for mass production of antimicrobial peptide
WO1999037664A1 (en) * 1998-01-22 1999-07-29 Samyang Genex Corporation Novel peptides having biological activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GARCIA, GREGORY E. ET AL: "Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro", XP002158848, retrieved from STN Database accession no. 133:54732 *
GARCIA GREGORY E ET AL: "Botulinum B toxin activity is inhibited by Buforin I.", FASEB JOURNAL, vol. 12, no. 8, 24 April 1998 (1998-04-24), Meeting of the American Society for Biochemistry and Molecular Biology;Washington, D.C., USA; May 16-20, 1998, pages A1472, XP002158847, ISSN: 0892-6638 *
J. APPL. TOXICOL. (1999), 19(SUPPL. 1), S19-S22 *

Also Published As

Publication number Publication date
EP1179022A2 (en) 2002-02-13
CA2369369A1 (en) 2000-11-23
JP2003502023A (en) 2003-01-21
WO2000069895A2 (en) 2000-11-23
IL146411A0 (en) 2002-07-25
AU781608B2 (en) 2005-06-02
AU6197500A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
Tsujinaka et al. Synthesis of a new cell penetrating calpain inhibitor (calpeptin)
Schmidt et al. Proteolysis of synthetic peptides by type A botulinum neurotoxin
WO2000069891A3 (en) Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
FI942423A (en) Saccharin derivatives as inhibitors of proteolytic enzyme
AU617875B2 (en) Novel peptidase inhibitors
Schirmeister et al. Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition
MY137301A (en) Peptide analogs as irreversible interleukin-1b protease inhibitors
SG52659A1 (en) Saccharin derivative proteolytic enzyme inhibitors
IE800694L (en) Enzymatic producion of peptides.
Ásgeirsson et al. Properties of elastase from Atlantic cod a cold-adapted proteinase
NZ606504A (en) Modified proteases that inhibit complement activation
WO2000069895A3 (en) Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
DE60126966D1 (en) TGF-BETA INHIBITORS AND METHODS
DE3462039D1 (en) Peptide derivatives, their preparation and use as elastase inhibitors
EP0458937A4 (en) Variants of pai-2
BR9911891A (en) Proteases fused to subtilisin inhibitor variants of streptomyces
Fournié-Zaluski et al. Differential recognition of “enkephalinase” and angiotensin-converting enzyme by new carboxyalkyl inhibitors
KR890004724A (en) New protease preparations
WO2007125142A8 (en) Antimicrobial linear peptides
AU1503697A (en) Method for cleaving chimeric protein using processing enzyme
WO2002085934A3 (en) Antibacterial peptides, compositions containing same and uses thereof
Christner et al. Lipohexin, a New Inhibitor of Prolyl Endopeptidase from Moeszia lindtneri (HKI-0054) and Paedlomyces sp.(HKI-0055; HKI-0096) II. Inhibitory Activities and Specificity
Fujiwara et al. Inactivation of pyroglutamyl aminopeptidase by L-pyroglutamyl chloromethyl ketone
Swanson et al. The identification of prolyl endopeptidase in bovine lenses: a preliminary report
Han et al. Inhibition of α-chymotrypsin with thiol-bearing substrate analogues in the presence of zinc ion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 61975/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2369369

Country of ref document: CA

Ref country code: CA

Ref document number: 2369369

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618311

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000948495

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000948495

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642